AndrewThomasKentMD

PubMed

• 3 citations
  Higher-dose venetoclax with measurable residual disease-guided azacitidine discontinuation in newly diagnosed acute myeloid leukemia.
  Jonathan A Gutman, Amanda Winters, Andrew Kent, Maria Amaya, Christine McMahon, Clayton Smith, Craig T Jordan, Brett Stevens, Mohammad Minhajuddin, Shanshan Pei, Jeffr...> ;Haematologica. 2023 Oct 1
• Top advances of the year: Leukemia.
  Andrew Kent, Daniel A Pollyea> ;Cancer. 2023 Apr 1
• 3 citations
  Beyond αβ T cells: NK, iNKT, and γδT cell biology in leukemic patients and potential for off-the-shelf adoptive cell therapies for AML.
  Andrew Kent, Lyndsey S Crump, Eduardo Davila> ;Frontiers in Immunology. 2023 Jan 1
• 4 citations
  Chimeric non-antigen receptors in T cell-based cancer therapy.
  Jitao Guo, Andrew Kent, Eduardo Davila> ;Journal for Immunotherapy of Cancer. 2021 Aug 1
• 4 citations
  Delayed Tracheostomy in a Patient With Prolonged Invasive Mechanical Ventilation due to COVID-19
  Ian C Holmen, Andrew Kent, Stephanie Lakritz, Claire Brickson, Katarzyna Mastalerz> ;Cureus. 2020 Jun 15
• 85 citations
  A central role for Notch in effector CD8 + T cell differentiation
  Ronald A. Backer, Christina Helbig, Rebecca Gentek, Andrew Kent, Brian J. Laidlaw, Claudia X. Dominguez, Yevan S de Souza, Stella E. van Trierum, Ruud van Beek, Guus F...> ;Nature Immunology. 2014 Dec 1
• 19 citations
  Nod-Like Receptors: Key Molecular Switches in the Conundrum of Cancer
  Andrew Kent, J. Magarian Blander> ;Frontiers in Immunology. 2014 Apr 23
• Join now to see all